Abbreviations: HSP, heat shock protein; IC 50 , 50% inhibitory concentration; Topo II, topoisomerase II
INTRODUCTION
Cell based assays are widely used in drug discovery because the assessment of molecular interaction occurs within the context of a living cellular environment (Baker, et al., 2007) . Many bioactive compounds, inhibiting the growth of cancer cells, have been isolated using a cell-based screen (Kakeya, et al., 2002; Kawada, et al., 2009) . In most instances, the molecular target for newly isolated compounds remained unknown. The identification of a plausible target is sometimes possible based on the results of cell-based assays, however, the exact target must be proven by enzymatic assays, analyses of binding proteins, or genetic methods employing a siRNA (Kazami, et al., 2006; Sato, et al., 2007; Teruya, et al., 2005) . The confirmation of the molecular targets, however, is usually a difficult and time-consuming process.
The multidimensional phenotype profiling approaches have a capacity to generate a testable hypothesis related to the mechanism of action and eventual off-target effects of new compounds. The differential sensitivity of the panel of cancer cell lines to the compounds has been used to identify their molecular target(s). The most commonly used assay, NCI 60 antitumor screen, allowed to identify benzolactone enamide as an inhibitor of V-ATPase (Boyd, et al., 2001) . The other panel consisting of 39 different cancer cell lines identified the compound encoded as ZSTK474 to be the inhibitor of phosphatidylinositol 3-kinase (Yaguchi, et al., 2006) . Recent advances in the field of molecular biology provided a wide spectrum of methods suitable for target identification.
The application of the connectivity map, developed by Golub and co-workers that uses gene expression signature for profiling , led to the identification of a class of HSP90 pathway modulators (gedunin and celastrol) (Hieronymus et al 2006) .
The cell morphology-based profiling (Abassi, et al., 2009; MacDonald, et al., 2006 ) and the activity-based proteomic profiling (Leung, et al., 2003) are also used for molecular target identification.
Compared with gene expression profiling which can simultaneously measure the expression of more than 20,000 genes, proteome analysis provides us only with the opportunity to trace at most 1,000 protein spots. However, any change of molecular weight and isoelectric point of proteins after posttranslational modification is often detectable as a mobility shift of protein spots in two-dimensional gel electrophoresis (2DE) analyses. Since biologically active compounds affect cellular processes and induce changes in both the expression levels and modification of proteins, proteome profiling is an informative approach for investigating the effects of the compound. Indeed, several research groups have shown that biologically active compound alter the proteome (Cecconi, et al., 2007; Towbin, et al., 2003) . Recent advances in two-dimensional difference gel electrophoresis (2D-DIGE) have allowed to measure the abundance of each protein spot between different gels with a high accuracy due to introduction of an internal standard (Van den Bergh and Arckens, 2004) . With 2D-DIGE, the abundant proteomic expression data obtained from different treatments can be collected, and the expression patterns can be compared. In this study, we have used 2D-DIGE to perform a comprehensive proteome analysis of protein expression changes caused by the treatment of cancer cells with the anticancer drugs claimed to possess the "exact mechanisms of action".
It is well known that the anticancer drugs of known and similar mechanism of action such as doxorubicin and daunorubicin, both classified as anthracyclines, are clinically active against different types of cancers. Doxorubicin is mainly used in the treatment of solid tumors, while daunorubicin shows activity in hematologic malignancies. The other case is cisplatin and oxaliplatin, the former active against lung and ovarian cancers, and the latter active against colon cancer. Keeping in mind a subtle difference in clinical activity of the compounds of similar "exact mechanism of action", we have made an attempt to establish differential proteins profiles in cancer cells treated with anticancer agents representing several main mechanisms of action, including also several compounds possessing the same well-established mechanism of action. The proteomic profiling of mechanism of action may play essential role in the planning of individualized chemotherapy of cancer patients, once the correlation between drug sensitivity and the drug-induced proteomic profile is found.
Here, we report the procedure and results of the proteome analysis, using 2D-DIGE that revealed significant similarities in protein expression changes induced by the compounds belonging to the same class. Furthermore, we were also able to distinguish subtle differences among compounds attacking the same molecular target, however, in a different way.
RESULTS

Proteomic Patterns of Geldanamycin and Radicicol-Treated HeLa Cells are Similar
Geldanamycin (1) and radicicol (2) are well-known HSP90 inhibitors (Schulte, et al., 1998; Whitesell, et al., 1994) . HSP90 is one of the targets for cancer therapeutics, and 17-AAG, a derivative of geldanamycin is under clinical trials (Nowakowski, et al, 2006) . First, we have determined cell growth inhibitory effect of HSP90 inhibitors against HeLa cells using a WST-8 assay (Fig. 1A) . The IC 50 growth inhibitory concentration of geldanamycin against HeLa cells was approximately 0.05 µM in a 48-h treatment. HeLa cell growth was not affected at concentrations lower than 0.01 µM, while a complete growth inhibition was observed at concentrations greater than 0.1 µM. The IC 50 of radicicol against HeLa cell growth was approximately 1 µM.
Next, we have investigated the relationship between proteomic changes after exposing HeLa cells to effective concentrations of the compounds, e. g., 0.005, 0.05, 0.5, 5, and 10 µM for geldanamycin and 10 µM for radicicol; the results are shown in Fig. 1B .
In this analysis, 775 spots in 2DE gels were matched on all gel images and quantified by 2D-DIGE system software, resulting in 282 spots that were selected by ANOVA (P < 0.01) and Dunnett's test (P < 0.01) (see Table S1 ). Then, hierarchical cluster analysis was performed. The results were displayed in the form of a heat map and a tree diagram (Fig.   1B ). In the heat map, the spots with increased expression are indicated in red, and the spots with decreased expression are indicated in green. As indicated in the tree diagram and the heat map, the patterns of protein expression were similar at geldanamycin concentrations greater than 0.5 µM.
To simplify the statistical evaluation of the 2D-DIGE experiments, the spots that were modified significantly between groups were typically selected using ANOVA test and a volume ratio filter of no less than 2-fold for 3 biological replicates per group (Karp and Lilley, 2005) . Using these parameters, 17 spots were selected and a similar result for the cluster analysis was obtained (data not shown).
In HSP90 inhibitor-treated cells, HSP70 and HSP27 have been reported to be upregulated (Maloney, et al., 2007; McCollum, et al., 2006) . To classify test compounds using proteomic profiling, the identity of each protein spot is not necessary, however, it is important to confirm whether proteomic change of geldanamycin-treated cell matches that in previously reported results. Peptide mass fingerprinting identified 20 spots out of the total number of spots that had been significantly affected by the treatment with geldanamycin and other compounds (Table S2 and S3). The application of ANOVA test selected 15 out of 20 spots and the mean ratios between control and inhibitor-treated cells were tabulated (Table 1) . Spots 1114 and 1127, which were identified as heat shock 70 kDa protein 1 (HSP70, HSPA1B), were upregulated more than 7-fold when compared with control. At 0.05 µM geldanamycin, HSP70 upregulation was also detected, but the magnitude of increase was lower compared with higher concentrations. The expression level of spot 2382, identified as heat shock protein beta-1 (HSP27, HSPB1), also reached a plateau, as did HSP70. By Western blot, both HSP70 and HSP27 were upregulated to similar extent at concentrations greater than 0.05 µM (Fig. 1C) .
The upregulation of mitochondrial heat shock proteins (HSP9B, HSPD1) and protein disulfide isomerase and downregulation of eukaryotic elongation factor 2 (EEF2), fascin (FSCN1), adenylyl cyclase-associated protein 1 (CAP1), and aldo-keto reductase family 1 member C2 (AKR1C2) were observed in geldanamycin-treated HeLa cells. It is very important to indicate that the concentration corresponding to the IC 50 in the WST-8 assay is insufficient to induce any obvious changes in the proteomic analysis. It is more reasonable to use concentrations at which cell growth is nearly completely inhibited.
When the cells were exposed to 0.5 µM geldanamycin, the amount of HSP70 increased in time-dependent manner and reached a plateau after 18 h ( Fig. 1 D and E) .
Since long incubation with test compounds may be associated with secondary effects, such as apoptosis, we purposely avoided long exposures. Instead, we performed a subsequent proteomic analysis of HeLa cells after 18 h exposure to test compound.
Radicicol (2) is another HSP90 inhibitor that structurally differs from geldanamycin (1). The expression patterns between radicicol-and geldanamycin-treated cells were compared by 2D-DIGE. Similar responses were observed between geldanamycin-and radicicol-treated cells (Fig. 1B and Table 2 ). The spots representing eukaryotic elongation factor 2, fascin, and adenylyl cyclase-associated protein 1 were downregulated during both treatments. These results strongly suggest that compounds inhibiting the same molecular target generate similar proteomic profiles.
Proteomic Analysis of HeLa Cells Treated with Compounds of Known Mechanisms of Action
To compare the proteomic patterns in HeLa cells treated with the compounds whose targets are known, the well-characterized chemical entities were selected for proteomic analysis (Table 2) . Based on experience with geldanamycin, the proteomic analysis of above mentioned compounds was performed at the concentrations higher than their respective IC 50 values. Their growth inhibitory effects were determined by WST-8 assay and are presented as the IC 50 values in Table 2 . The concentrations used for the exposure of HeLa cells during proteomic profiling experiments were those inhibiting cell growth by 80% or more ( Table 2) .
As previously indicated, the proteomic analyses of HeLa cells were performed after 18 h exposure to a test compound. Since the master gel of geldanamycin-treated cells from the previous experiment ( Fig. 2A ) was used as the template, the numbering of the spots remained the same in all experiments. Three hundred eighteen spots in the 2DE-gel were matched on all gel images, and quantified by 2D-DIGE software; 298 of them were selected by ANOVA (P < 0.01) and Dunnett's test (P < 0.01) (see Table S4 ). The data were calculated and visualized by cluster analysis programs (Fig. 2B) ; the mean ratio of the identified spots and the results of statistical analysis are listed in Table 4 .
As indicated in the tree diagram (Fig. 2B ), the inhibitors of V-ATPase (bafilomycin A1 and concanamycin A), tubulin (nocodazole and vinblastine), and actin (cytochalasin D and jasplakinolide) were classified into separate clusters. The spots that changed significantly between groups were selected using ANOVA and a volume ratio filter of no less than 2-fold (Karp and Lilley, 2005) , yielding 47 spots and leading to a similar result of cluster analysis (data not shown).
We also noticed that MG-132, a proteasome inhibitor, generated a similar pattern as the HSP90 inhibitors did. The amount of protein in the HSP70 spots (spots 1114 and 1127) also increased in MG-132-treated cells, as did those observed in geldanamycinand radicicol-treated cells (Table 3 ). In contrast, the HSP27 showed an aberrant pattern.
Although HSP90 inhibitors increased the amount in spots 2372 and 2382, which were identified as HSP27, the MG-132 treatment increased only the spot number 2372.
Other noteworthy changes were as follows: 1) the inhibitors of actin, cytochalasin Iejimalides, 24-membered macrolides, were originally isolated from marine tunicate as potent antitumor compounds (Nozawa, et al., 2006) . We recently found that iejimalides inhibited V-ATPase (Kazami, et al., 2006) . We have analyzed HeLa cells treated with iejimalide A (3) or iejimalide B (4) at 30 nM by 2D-DIGE. We combined the proteome data from iejimalides-treated HeLa and compared with the proteomic profiles generated by the treatment of HeLa cells with 19 well-characterized compounds.
Iejimalide A (3) and B (4) were clustered into the same tree as the other V-ATPase inhibitors (e.g., bafilomycin A1 (5) and concanamycin A (6)) ( Fig. 2C) . Recently, it was reported that iejimalides affect actin depolymerization (Fürstner, et al., 2007) , however, iejimalide A and B did not match the cluster representing actin inhibitors. These results indicate that the primary target of iejimalides in HeLa cells is V-ATPase, at least at concentration used in our experimental setting.
Flow Cytometry of HeLa Cells Treated with ICRF-193 and Etoposide
The proteomic analysis of HeLa cells treated with the two structurally different inhibitors of topoisomerase II (topo II), and etoposide (8) revealed significant differences; both compounds were not able to form a single cluster (Fig. 2B ).
To confirm this finding, we measured the distribution of cellular DNA in HeLa cells by flow cytometry, after treating asynchronous HeLa cells with varying concentrations of ICRF-193 or etoposide for 48 h.
The basic amount of DNA in a haploid nucleus is given the value C. In the absence of inhibitors, we observed typical 2 peaks, corresponding to cell population with 2C and 4C DNA content. The treatment of HeLa cells with ICRF-193 resulted in decreasing the height of the 2C peaks at concentrations higher than 1 µM, while the 4C population increased (Fig. 3A) . On the other hand, etoposide used at concentrations higher than 1 µM also increased the 4C peaks, but without any obvious accumulation of the peaks containing 8C DNA, contrasting the effect of (Fig. 3B) . also studied in time-dependent fashion, using equimolar concentration of 10 µM for both test compounds. The ICRF-193 induced a gradual accumulation of 4C population up to 18 hour, then the generation of polyploidy (8C) in HeLa cells was observed (Fig. 3C) beyond that time point.
Etoposide was not able to induce polyploidy in HeLa cells, even during 72-h exposure (Fig. 3D) . Despite the presence of common mechanism of action (topo II inhibition), the final biological effects are different, and two compounds were clustered into different cluster in our proteomic analysis.
DISCUSSION
In this study, we have performed a proteomic analysis of HeLa cancer cells treated with well-characterized anticancer agents using a 2D-DIGE system. The target proteins of these compounds are known at the cellular level and represent the targets for cancer therapeutics, such as the proteasome and microtubules. Each compound induced a characteristic proteomic pattern and hierarchical clustering exactly classified the compounds according to their respective targets, such as HSP90, tubulin and V-ATPase (Fig 2B) .
Topo II inhibitors are still good candidates for molecular targeted drugs in cancer therapy. Topo II as a single target can be inhibited by two distinct mechanisms. One is exercised by a catalytic site inhibition, resulting in the formation of a non-cleavable complex and is characteristic for ICRF-193, a topo II inhibitor (7) (Roca, et al., 1994; Tanabe, et al., 1991) . The other mechanism involves the stabilization of DNA cleavable complex, which further leads to double-strand DNA breaks and damage; etoposide (8), a topo II poison, plays essential role in this mechanism (Liu, 1989) . As reported by Ishida et al., etoposide blocked the progression of cells to M phase, while ICRF-193 only delayed the transition from S to M phase and induced polyploidization in HeLa cells . Thus, both compounds are topo II inhibitors but act through disparate mechanisms (Andoh and Ishida, 1998) . Their proteomic phenotypes differed and did not fall into the same cluster. Moreover, their cellular phenotypes, as determined by the analysis of cellular DNA distribution (Fig. 3) differed as well. One may conclude that such compounds can be classified into different clusters from proteomic point of view, despite exercising their biological activity through the same molecular target, or their exact mechanism of action may be revised. An inability to share a common cluster might be caused by an excessive off-target effect. To clarify that matter it seems important to know which mechanism determines anticancer activity against particular type of cancer or contributes mainly to toxicity. Gathering more data will be of a great importance in the evaluation of undesired effects as well.
So far, our proteomic profiling of mechanism of action of anticancer agents appeared to be helpful in the identification of the mode of action of iejimalides, a newly isolated natural products, as being inhibitors of V-ATPase (Fig. 2C) . The comparison of the proteomes of the cells treated with a newly isolated compound versus well-characterized compounds can lead to the testable hypothesis on general mechanisms of action as in the case of other profiling approaches such as the genetic one.
Despite of recent enthusiasm, one may anticipate certain limitations of our proteome profiling system. To name a few, the following factors may become the obstacle in the system. 1) The suspected target for test compound is not expressed or is not functional (mutation, SNP) in HeLa cells. 2) The suspected target was not validated yet by known standards.
3) The changes induced in proteomic profile by a test compound are not sufficiently distinct due to the appearance of limited number of spots in 2D gels. 4) The presence of several molecular targets may complicate the analysis; therefore, an interpretation of data will have to be made with great caution.
Our proteomic analysis matched methyl-gerfelin with two V-ATPase inhibitors, however, its biological effects in cell system (upregulation of pH, Figure S1 ) were not confirmed. The newly developed by us technology of a small molecule affinity matrix, revealed a strong interaction with glyoxalase I, supposedly a direct target molecule (Kawatani et al., 2008) . The lack of standards for glyoxalase I inhibitors in proteomic analysis led to the clustering with the V-ATPase inhibitors. Therefore, the expansion of the system by variety of compounds with increased precision and accuracy of the system in classifying compounds into groups will lead to the well-established mechanism of action. The compounds not matching any known mechanisms may be considered as the probes for searching not yet identified molecular targets.
The case of jasplakinolide and cytochalasin D may well illustrate some of the obstacles, both compounds affect actin by inhibiting its depolymerization (Bubb, et al., 1994) and polymerization (Cooper, 1987) , respectively. Although their effects on actin are opposed, both compounds increased the levels of actin and were included into the same cluster in this experiment. However, we noted the presence of several unidentified spots that did not correlate to these two compounds. Further investigation should clarify the differences between polymerizing and depolymerizing effects of these two inhibitors with the application of proteomic analysis.
The 2DE-based proteomic analysis is generally a time-consuming process during the initial stage of system development, since the identification of almost all protein spots is essential. Once this stage is completed and a database is created, one can analyze the proteomic profiles of many chemical entities by comparing them with those contained in the database, without necessity of additional protein spots identification. This is a huge advantage of this technique. Nevertheless, in the case of dramatic change in the expression levels among not yet identified spots, the characterization of those spots will be very informative in target identification, or at least these compound-specific spots may serve as an important marker of biological activity. The agents inducing microtubules depolymerization may serve as an illustration of where a compound does not directly cause the modification of a protein spot, and is rather an artifact related to its primary mechanism of action. More specifically, the antimicrotubular agents cause cell cycle arrest in M-phase, preventing cell division due to the lack mitotic spindle formation and the nuclear envelope remains intact. Under normal condition the envelope is broken down and its component, lamin, is released (Parnaik, 2008) . The release of lamin is decreased after the exposure of the cells to antimicrotubular agents (Table 3) and may serve as a marker of compound's effectiveness, albeit, not being a target.
The treatment of HeLa cells with MG-132 increased the expression of HSP70, thus confirming already reported phenomenon (Kawazoe, et al., 1998) and the cluster analysis tree positioned this compound close to the group of HSP90 inhibitors. However, slight differences were observed, namely, HSP90 inhibitors increased both spots of HSP27 (nos. 2372 and 2382), while the MG-132 increased only spot number 2372. Because HSP27 has been reported to enhance proteasome-dependent protein degradation (Parcellier, et al., 2006; Parcellier, et al., 2003) , this result may suggest the presence of at least two forms of HSP27, one of which is probably involved in proteasome-dependent protein degradation.
Based on these results, we propose that the expression levels of HSP27 spots may determine the classification of compounds either to HSP90 inhibitor or to proteasome inhibitor class of compounds. Particularly, the expression ratio of HSP70 and HSP27 spots will play a role of differentiating marker for either class.
So far, we have examined only 19 compounds, reaching an ability to classify the compounds according to their mechanism of action. The expansion of the proteomic profiling by the other types of compounds with different mode of action will make the system fully operating for the prediction of biological activity of newly discovered natural products or synthetic compounds. Already, we were able to classify a newly synthesized derivative of natural product with unknown mechanism of action as an inhibitor of topoisomerase II (data not shown). For that purpose, the extensive process of system validation using the chemical library of NPDepo (Tomiki, et al., 2006 ) is under way. Since the assay is primary based upon the only one cancer cell line, it is reasonable among cell line are observed. As the natural consequence of the recent promising results, there is the need to include protein interaction map that should enforce the discovery of new target molecules. One may easily indicate a protein spot which may become a marker, however, one should explore the path from the marker up to the protein responsible for that change; then the protein may be claimed to be a target, or in other words, the object of a primary attack by an active substance.
In summary, the proteomic profiling based on the 2D-DIGE is an important supplement to other multidimensional phenotypic profilings and its capacity may be extended by the introduction of the different pathological phenotypes represented by cancer cells, leading, e.g., to identification of specific biomolecules as well. Monoclonal anti-a-tubulin (clone DM1A) was purchased from Sigma (St. Louis, MO).
The reagents for Western blotting were purchased from Thermo Scientific (Rockfort, IL).
All reagents were reagent-grade.
Cell Culture
HeLa cells were cultured in Dulbecco's Modified Eagle's Medium (D-MEM, Sigma, St. Louis, MO), supplemented with 10% fetal bovine serum, at 37°C in a humidified CO 2 incubator (5% CO 2 -95% air).
Cell Growth Assay
HeLa cells were seeded at 2 × 10 3 cells per well in a 96-well culture plate and incubated overnight, test compounds were added to the medium at various concentrations.
After 48 h, cell number was determined using Cell Count Reagent SF (Nakalai Tesuque, Kyoto, Japan) according to the manufacturer's protocol. Briefly, 10 µL of WST-8 solution (mixture of WST-8 and 1-methoxy-5-methylphenazinium methylsulfate) was added to the wells and incubated for 2 h, and cell number was assessed by measuring the absorbance at 450 nm on a microplate reader (BIO-RAD, Hercules, CA)
Preparation of Cell Lysates for Proteomic Analysis
HeLa cells (3 x 10 5 cells) were seeded on a culture dish (35-mm diameter) containing 3 mL of medium and incubated overnight. Each assay was done in triplicates.
The cells were exposed for 18h to the designated concentrations of test compounds. Cells were washed thrice with ice-cold phosphate-buffered saline (PBS), removed by a rubber policeman and collected by centrifugation at 4000 rpm for 3 min at 4°C in a microcentrifuge (KUBOTA 3700, Kubota, Tokyo, Japan).
After being washed once with PBS, cells were suspended in sample buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, buffered to pH 8.5) for 2D-DIGE and disrupted with a TOMY UR-20P sonicator (TOMY Co. Ltd., Tokyo, Japan). Cell lysates were treated with 1.25 U/µL benzonase (Merk, Darmstadt, Germany) for 60 min on ice and centrifuged at 12,000 rpm for 3 min at 4°C. Supernatants were stocked at -80°C until use.
Labeling of Cell Lysates and 2DE
Protein concentration was determined by Bradford procedure using the Protein Assay kit (BIO-RAD, Hercules, CA). Fifty micrograms of protein was labeled with 200 pmol of CyDye DIGE Fluor minimal dyes (GE Healthcare, Buckinghamshire, UK) according to the manufacturer's instructions (Cy3 and Cy5 for samples and Cy2 for internal control, consisting of equal parts of all samples in an experiment).
Samples were applied by rehydration onto immobilized pH gradient strips (24 cm, pH 3-10, nonlinear gradient, GE Healthcare) and subjected to isoelectrofocusing in an IPGphor IEF system (GE Healthcare). Strips were incubated in equilibration buffer (6 M urea, 30 % glycerol, 2% SDS, 50 mM Tris-HCl pH 8.8) containing 1% DTT for 15 min and then incubated in the same buffer containing 2.5% iodoacetamide for 15 min. Strips were transferred to the tops of 10% polyacrylamide gels and electrophoresed overnight in a DALT-twelve TM apparatus (GE Healthcare).
After electrophoresis, gels were scanned using a Typhoon TM 9400 imager at 100 dpi resolution (GE Healthcare). Gel analysis was performed using DeCyder BVA 6.5 (GE Healthcare), a 2DE analysis software package, following the manufacturer's recommendations. The estimated number of spots for each codetection was set to 3000.
Experimental Design and Data Processing for 2DE Profiling
To perform visual 2DE protein profiling of compound-treated HeLa cells, experiments were divided into subsets. We used the spot number of the master gel as the common master number for all of the experiments. The gel that contained the most spots in the first experiment (analysis of HeLa cells treated with various concentrations of geldanamycin) was chosen as the master gel.
In a representative subset of experiments, we used 3 compounds and DMSO. HeLa cells were treated with these solutions, and proteomic analysis was performed. All samples of compound-and DMSO-treated cells were prepared in triplicate. Equal parts of all samples in a subset of experiments were labeled with Cy2 CyDye Fluor as an internal standard.
To match the common master numbers between subsets of experiments, image files were imported into the project file, including the master gel, and spot maps of the images were matched to the master gel image using the BVA modules of DeCyder 6.5. More than 650 spots were usually matched in all the analyzed gels of a subset. The volume of each spot was obtained as a ratio of the Cy3-or Cy5-labeled sample compared with the corresponding Cy2 signal of the internal standard. Then, the volume of each spot was normalized using the average of the corresponding control value from the DMSO-treated HeLa cells.
Normalized volume data in subsets of experiments were combined, and only spots that did not lack data in any of the gels were selected. Subsequently, the spots that showed significant changes after compound-treatment were selected by ANOVA (P < 0.01) and Dunnett's test for post hoc analysis. For cluster analysis, the normalized volumes were calculated using the means of uncentered correlation with centroid linkage using Cluster 3.0 (Hoon, et al., 2004) and visualized using Java TreeView (Saldanha, 2004) .
Statistical calculations, such as nonrepeated measures ANOVA and Dunnett's test for post hoc analysis (Sheskin, 2000) , were performed using Microsoft Excel with a statistical macro (ystat2006, Igaku Tosho Shuppan, Tokyo, Japan) and R version 2.9.2 (http://cran.r-project.org/).
Western Blotting
Cell lysates were resolved by 10% SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% nonfat dried milk in TBS-T buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05 % Tween 20), followed by incubation with primary antibody (1:1000 dilution) in TBS-T. The detection was performed using horseradish peroxidase-labeled secondary antibodies (1:1000 dilution) and enhanced chemiluminescence detection reagent. The expression of tubulin was also measured and used as an internal control.
Flow Cytometry
Cells were treated with 0.25% trypsin for 5 min to remove them from the dish, Asterisks indicate significant differences from respective controls (* P < 0.05, ** P < 0.01). 
